Pre­ci­sion Bio­Sciences hands glob­al rights to CAR-T can­di­date; Sagimet clos­es un­der­writer’s op­tion to buy stock

Pre­ci­sion Bio­Sciences said Tues­day night that it has closed a deal with Imu­gene, hand­ing off glob­al rights of its al­lo­gene­ic CAR-T can­di­date known as az­er-cel.

The deal in­cludes $21 mil­lion up­front to Pre­ci­sion, plus a po­ten­tial $8 mil­lion pay­ment if Phase Ib dos­ing in a large B-cell lym­phoma pa­tient pop­u­la­tion is suc­cess­ful. Specif­i­cal­ly for az­er-cel, Pre­ci­sion can re­ceive up to $198 mil­lion in mile­stone pay­ments and roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER